Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01261
|
|||||
| Drug Name |
Nadolol
|
|||||
| Synonyms |
(2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol; (2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol; 2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol; 5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol; Alti-Nadolol (TN); Anabet; Anabet (TN); Apo-Nadol (TN); Corgard; Corgard (TN); Corgaretic; Corzide (TN); Nadic; Nadolol (JP15/USP/INN); Nadolol [USAN:BAN:INN:JAN]; Nadololum; Nadololum [INN-Latin]; Novo-Nadolol (TN); SQ 11725; SQ-11725; SQ11725; Solgol; Solgol (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Angina [ICD11:BA40] | Approved | [1] | |||
| High blood pressure [ICD11:BA00] | Approved | [1] | ||||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H27NO4
|
|||||
| Canonical SMILES |
CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O
|
|||||
| InChI |
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
|
|||||
| InChIKey |
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
|
|||||
| CAS Number |
CAS 42200-33-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 309.4 | Topological Polar Surface Area | 82 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
855594
,7847498
,7980059
,8149963
,8175898
,10321209
,11335602
,11360841
,11364537
,11367099
,11369661
,11372751
,11373904
,11377823
,11461813
,11466846
,11467966
,11485128
,11486372
,11489362
,11491401
,11492008
,11495457
,12013396
,26612453
,26680146
,34705082
,46505509
,47216720
,47440192
,47515259
,48035045
,48110397
,48416301
,49995587
,50105273
,53787811
,56413054
,56422422
,57312272
,75643004
,85787107
,92124849
,92125681
,92307845
,99301515
,99351138
,103189209
,103913689
,104169962
|
|||||
| ChEBI ID |
ChEBI:7444
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OATP1A2 | Transporter Info | Organic anion transporting polypeptide 1A2 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Nadolol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39. | |||||
| 3 | Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.